Floatz logo

Naltrexone

Binge-Eating Disorder

Yale UniversitySmall moleculePhase 2/3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Binge-Eating Disorder cohort.

Asset / SponsorPhaseRating
Wellbutrin
Yale University
Phase 2/3BB
Topamax
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2/3B
Methylphenidate
Centre for Addiction and Mental Health
Phase 2B

Same molecule, other indications

Naltrexone is also rated in:

alcohol dependenceDormant
BBB
Indicative ·
79 / 100
View asset →
nicotine dependenceDormant
BBB
Indicative ·
76 / 100
View asset →
osteoarthritisDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →